General
Department of Public Safety Announcement Letter April 27, 2023
Caregiver Criminal History Screening Program Letter April 28, 2023
Overview of IDEMIA New Mexico Applicant Solution PowerPoint
New Mexico Application Registration Process
New Mexico Non-Resident/Fingerprint Card Scan Overview PowerPoint
Fingerprint background check services Frequently Asked Questions (FAQs)
Map of Fingerprint Location Sites
List of acceptable IDs needed for enrollment
Guidance on Multi-factor Authentication Applications
IDEMIA Background Check Result Access PowerPoint
Northwest Region Health Promotion Team
The CDC and FDA have streamlined COVID-19 vaccine recommendations, authorizing the use of bivalent COVID-19 vaccines for all recommended doses. In addition, previously unvaccinated individuals ages 6 and older are now recommended to receive one dose of a bivalent COVID-19 vaccine, and people ages 65 and older and those with immune compromise can receive a second bivalent vaccine. The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.
Health Council Priorities FY23 rev 3-17-23
The U.S. Drug Enforcement Agency (DEA) recently issued an alert regarding overdose deaths in the US linked to Xylazine, a non-opioid central nervous system depressant. It is used as a sedative, anesthetic, muscle relaxant, and analgesic in veterinary medicine and has not been approved for use in humans. Xylazine is usually mixed with other illicit drugs, like fentanyl, because it causes the effects of opioids to last longer. In New Mexico, six xylazine-involved deaths were reported in the last five years. Xylazine is an unscheduled drug that is easily accessed, so its presence in the illicit drug supply may increase over time, due to its low cost. Reports indicate that xylazine, alone or in combination with other drugs, is administered by injecting, snorting, swallowing, or inhaling it.
Stakeholder engagement and participation is critical, and required, to ensure we capture the information needed to make the best decisions for the Department of Health, Developmental Disabilities Supports Division service delivery system for the Developmental Disabilities (DD) Waiver, Mi Via (MV) Waiver and the Medically Fragile (MF) Waiver.
NM ACQ Subcommittee Initial PowerPoint
NM ACQ Mathematical Rate Study PowerPoint
For any question not answered here, please contact Public Consulting Group via email or phone at NMHCBSRateStudy@pcgus.com or (833) 528-1736.